

FDA Mandates New Safety Controls for Long-Actiong Beta Agonists

The US Food and Drug Administration (FDA) announced that manufacturers of long-acting beta agonists (LABAs) must now state on product labels that asthma patients must not take LABAs on a long-term basis unless their condition cannot be adequately controlled with other medications such as inhaled corticosteroids. [Click Here](#) for more information.